Compare Omnicom Group Inc. (OMC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Omnicom Group Inc. trades at $76.42 (market cap $20.97B), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: Omnicom Group Inc. is far larger — about 9.8× Recursion Pharmaceuticals Inc's market cap, and Omnicom Group Inc. pays a 4.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OMC | RXRX | |
|---|---|---|
Market Cap | $20.97B | $2.14B |
Volume | 2,092,899 | 30,789,535 |
Sector | Media | Health |
52-Week High | $88.94 | $6.79 |
52-Week Low | $67.27 | $2.84 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | $29.05B | $1.66B |
Dividend Yield | 4.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.5M. Recent business developments include significant new billings of $3.3B in H1 2026 and leadership recognition in Gartner reports. Analyst consensus is mixed with 32% buy ratings but a $100.50 price target suggesting 34% upside potential.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.86) and dividend yield, though recent earnings misses and high P/E ratio of 206.62 raise concerns. Key risks include advertising market volatility and debt levels, while catalysts include AI integration and post-merger synergies from the Interpublic acquisition.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
